It has been found in prostate cancer studies that IL-23 produced by MDSCs can promote the development of prostate cancer through activating androgen receptor pathways in castration-resistant prostate cancer (CRPC), promoting cell survival and proliferation in androgen deficiency. The gene discussed is AR; the disease is prostate cancer.